2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1512

Bone Structural Deficits in Rheumatoid Arthritis: Impact of Muscle Mass and Density
Abstract Number: 1513

FRAX Fracture Risk in Rheumatoid Arthritis – Assessments with and without Bone Mineral Density May Lead to Very Different Results in Individual Patients
Abstract Number: 1514

Symptoms of Depression and Anxiety Predict Worse Disease Activity and Functional Disability in a Cohort of Established Rheumatoid Arthritis Patients
Abstract Number: 1515

Could Increase Levels of Dickkopf-1 Protein be Considered As a Potential Biomarker for Bone Resorption in Joint and Periodontal Disease in Patients with Early Rheumatoid Arthritis?
Abstract Number: 1516

Evidence of Labial Salivary Gland Epithelial Cell Activation from Patients with Rheumatoid Arthritis and Sicca Symptomatology
Abstract Number: 1517

Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Abstract Number: 1518

Immunoglobulin Binding Protein (BiP), an Antigen for CCP Sero-Positive Rheumatoid Arthritis Patients, Can Result in a False Positive Quantiferon-Gold Tuberculosis Test
Abstract Number: 1519

How Much, and When, Does Autoimmune Thyroid Disease Increase the Risk of RA, and Does RA-Onset Impact the Risk of Autoimmune Thyroid Disease?
Abstract Number: 1520

RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year
Abstract Number: 1521

Disease Characteristics and Change of Arthritis Activity According to Treatment in Hepatitis B Surface Antigen Positive Rheumatoid Arthritis Patients
Abstract Number: 1522

Disease Burden in Rheumatoid Arthritis (RA) Patients Who Have Secondary Osteoarthritis (OA) Is Lower Than in OA but Higher Than in RA with No Secondary OA
Abstract Number: 1523

The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR
Abstract Number: 1524

Suppletion Therapy May be Warranted in RA Patients with Co-Existent Subclinical Hypothyroidism
Abstract Number: 1525

Pain, Physical Function, and Worry (But Not Depression and Poor Sleep) Lead to Greater Fatigue in RA
Abstract Number: 1526

Serum y-Neuropeptide Levels and Its Relationship with Body Fat Mass and Clinical Characteristics in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].